oxelumab
mAbexperimental
Oxelumab is a human monoclonal antibody designed for the treatment of asthma. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2009 (NCT00983658)
Timeline
Indications
Studied for
Mechanism of action
TNFSF4 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOxelumab ↗
- ChEMBLCHEMBL2108720 ↗
Also known as
- humab ox40l
- humab ox40l
- oxelumab
- r-4930
- r-4930 humab ox40l
- ro4989991
- ro-4989991
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01152619 | Phase 1 | Jul 1, 2010 | Roche |
| NCT00983658 | Phase 2 | Sep 1, 2009 | Genentech |
Showing 2 of 2 trials
Page 1 / 1